J&J’s Wu On Nurturing Innovation In Asia
Dong Wu, head of J&J Innovation, Asia Pacific, outlines to Scrip the group’s partnering approach in South Korea and the Asia Pacific in general. He also offers some tips to Korean companies that are keen to pursue global partnerships.
You may also be interested in...
Amid ongoing interest in accessing innovative assets, including those from South Korea, big pharma participants at a recent symposium in Seoul shared the ins and outs of the complex partnering process.
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.